SUDEEPPHRM1,213.50

Sudeep Pharma Ltd.

· Chemicals
₹ CrorePeersSUDARSCHEMSTYRENIXSHARDACROPREFEXRCFRALLISRAINPRIVISCLMcap ₹13,706 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
SUDEEPPHRM
FY26
SUDARSCHEM
FY26
STYRENIX
FY26
SHARDACROP
FY26
Peer
Median
Valuation — at last close
P/E78.29×453.04×20.53×10.34×20.53× +281%
P/B15.26×2.58×2.75×2.24×2.58× +491%
EV/EBITDA62.32×18.34×11.38×6.00×11.38× +447%
Market Cap₹13,706 Cr₹9,958 Cr₹3,755 Cr₹7,039 Cr₹7,039 Cr +95%
Growth
Revenue CAGR 3Y62.01%13.17%9.20%13.17%
Revenue CAGR 5Y39.33%16.08%17.07%17.07%
Net Income CAGR 3Y-3.05%-0.03%25.81%-0.03%
Revenue YoY (latest Q)5.39%7.14%9.03%7.14%
Net Income YoY (latest Q)88.00%166.37%-38.36%88.00%
Profitability
EBITDA Margin34.55%6.03%9.98%20.43%9.98% +246%
Net Income Margin27.14%0.42%5.32%12.93%5.32% +410%
Return on Common Equity19.25%0.58%13.38%21.70%13.38% +44%
Return on Capital Employed21.29%3.56%12.05%22.15%12.05% +77%
Return on Assets14.83%0.42%7.37%11.78%7.37% +101%
Credit & Quality
Total Debt/Equity0.17×0.55×0.23×0.00×0.23× -26%
Interest Coverage27.23×1.47×11.78×427.86×11.78× +131%
Scale — latest FY
Revenue / Total Income₹642 Cr₹9,787 Cr₹3,438 Cr₹5,268 Cr₹5,268 Cr -88%
Net Income₹174 Cr₹40.8 Cr₹183 Cr₹681 Cr₹183 Cr -5%
Total Assets₹1,175 Cr₹9,723 Cr₹2,483 Cr₹5,780 Cr₹5,780 Cr -80%
EPS₹15.5₹2.8₹103.98₹75.47₹75.47 -79%
Book Value per Share₹79.51₹490.96₹776.75₹347.71₹490.96 -84%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.